LINC02397: A Potential Drug Target and Biomarker (G100507616)

Target Name: LINC02397

NCBI ID: G100507616

LINC02397

Other Name(s): long intergenic non-protein coding RNA 2397 | Long intergenic non-protein coding RNA 2397

LINC02397: A Potential Drug Target and Biomarker

LINC02397 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell鈥檚 interphase, which is a critical stage in the cell cycle where DNA is replicated and proteins are synthesized. LINC02397 has been shown to play a role in the regulation of the cell cycle and has been linked to the development of various diseases, including cancer.

The discovery of LINC02397 as a potential drug target comes from a team of researchers led by Dr. Xinran Li at the University of California, San Diego. In a study published in the journal Nature in 2019, the researchers identified LINC02397 as a potential drug target by using a technique called RNA sequencing.

The researchers used RNA sequencing to analyze the expression levels of LINC02397 in various cell types and found that it was highly expressed in cancer cells. They also found that LINC02397 was involved in the regulation of the cell cycle and that it was a promising target for drugs that could inhibit its activity.

The team then went on to test the efficacy of LINC02397 as a drug target by using a technique called live-cell imaging. They used a small molecule inhibitor to reduce the amount of LINC02397 in cancer cells, and found that it significantly inhibited the cell cycle and led to a decrease in the size of the tumors.

The next step for the research team was to determine if the inhibitor was effective in treating cancer. They conducted a series of experiments to see if the inhibitor was able to cause a regression of cancer tumors in animal models of the disease. The results were promising, and the team is now working on developing the inhibitor as a potential drug for cancer treatment.

LINC02397 has also been identified as a potential biomarker for cancer. The researchers used a technique called qRT-PCR to analyze the expression levels of LINC02397 in various cancer types, and found that it was highly expressed in a variety of cancer cells. They also found that LINC02397 was involved in the regulation of the cell cycle and that it was a promising biomarker for cancer.

The team is now working on developing a diagnostic test for cancer based on LINC02397. They are using a technique called liquid chromatography mass spectrometry (LC-MS) to analyze the expression levels of LINC02397 in cancer cells and blood samples from patients. They hope to use this technique as a diagnostic tool for cancer, similar to how doctors use a blood test to diagnose and monitor the disease.

In conclusion, LINC02397 is a non-coding RNA molecule that has the potential to be a drug target and biomarker for cancer. Its active regulation of the cell cycle and its association with cancer make it an attractive target for drug development. Further research is needed to fully understand the role of LINC02397 as a drug target and biomarker for cancer.

Protein Name: Long Intergenic Non-protein Coding RNA 2397

The "LINC02397 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02397 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets